Him & Hers Health stock forecast: Third-party price targets
Hims & Hers Health is a US-based digital healthcare company offering subscription-led telehealth services, with its shares attracting attention from traders tracking growth, valuation and volatility. Explore third-party HIMS price targets and technical analysis.
Hims & Hers Health, Inc. (HIMS) is trading around $27.18 as of 3:30pm UTC on 2 February 2026, moving within an intraday range of approximately $26.49–$29.67 on Capital.com’s USD-denominated HIMS CFD feed. Past performance is not a reliable indicator of future results.
The stock is trading against a backdrop of recently reported Q3 2025 results, where Hims & Hers posted revenue of about $599 million, up roughly 49% year-on-year, alongside subscriber growth to nearly 2.5 million. These figures point to continued expansion of its direct-to-consumer telehealth model (Hims & Hers Health, 3 November 2025). Recent commentary has also highlighted ongoing discussions with Novo Nordisk over potential access to the weight-loss treatment Wegovy through the platform (Reuters, 10 December 2025), as well as upcoming high-profile marketing activity around a new national 'Big Game' advertising spot scheduled for early February 2026 (Yahoo Finance, 29 January 2026).
Him & Hers Health stock forecast 2026–2030: Third-party price targets
As of 2 February 2026, third-party Him & Hers Health stock predictions point to a broad dispersion of 12-month views, ranging from the high-$20s to around $60 per share. This range reflects differing assumptions around growth, profitability and valuation. These figures are quoted in US dollars per share as one-year price objectives and do not represent guaranteed outcomes.
BofA Securities (broker research)
BofA Securities (Bank of America) reduced its 12-month Hims & Hers Health price target to $29 from $32, while maintaining an underperform rating on the stock. The broker cites valuation concerns and softer growth expectations, pointing to ongoing investment needs and signs of weaker online revenue trends amid a more cautious demand backdrop (Investing.com, 8 January 2026).
Evercore ISI (initiation)
Evercore ISI initiates coverage of Hims & Hers Health with an in-line rating and a $33 12-month price target. The firm frames the target around expectations of continued revenue expansion and customer acquisition, while balancing growth prospects against competitive pressures and the investment required to scale the platform (MarketBeat, 12 January 2026).
BTIG Research (target revision)
BTIG Research trims its 12-month HIMS stock forecast to $60 from $85, while maintaining a positive rating on the stock. The analyst notes a reassessment of valuation and risk following a strong prior run-up, with the revised target still incorporating assumptions of sustained revenue growth and margin expansion amid evolving market conditions (Gurufocus, 2 February 2026).
Morgan Stanley (broker research)
Morgan Stanley reiterates an Equalweight rating on Hims & Hers Health with a $40 12-month price target. The note adopts a more cautious stance ahead of the company’s 2026 guidance announcement, highlighting prior share-price volatility and valuation considerations alongside ongoing growth investments (Investing.com, 20 January 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
HIMS stock price: Technical overview
The HIMS stock price is trading around $27.18 as of 3:30pm UTC on 2 February 2026, positioned below a broad cluster of daily moving averages, with the 20-, 50-, 100- and 200-day averages grouped near approximately 31, 34, 42 and 46 respectively. The 14-day RSI near 31.8 sits in lower-neutral territory rather than oversold, while an ADX reading just above 31 suggests an established trend environment rather than a range-bound market.
On the topside, the first reference sits near the classic R1 area around 33.4, with a sustained daily close above that zone bringing the higher R2 region near 39.7 back into focus. On pullbacks, initial support lies near the classic pivot around 30.1, while the 100-day SMA near 42.2 marks the next major moving-average reference. A decisive break below the pivot would increase the risk of a move towards the S1 band around 23.8 on the daily chart (TradingView, 2 February 2026).
This technical analysis is provided for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Him & Hers Health share price history (2024–2026)
The HIMS stock price has experienced a pronounced round trip over the past two years, moving from mid-$20s levels in late 2024 through a sharp rally and subsequent pullback into early 2026. The stock closed 2024 at about $24.23 on 31 December, before pushing higher through early 2025 and breaking above $40 in February. It briefly spiked to intraday highs above $73 around 19 February 2025, after which volatility increased.
By mid-2025, the stock was trading largely within a $50–65 range, with several moves above $60 across June and July. Momentum then faded into the autumn, with prices trending lower from the low-$60s in late September towards the high-$30s by early December.
Into year-end 2025, HIMS closed at $32.81 on 31 December and extended its decline in early 2026, sliding from above $35 at the start of January to $27.29 by 2 February 2026. This represents a substantial retracement from the February 2025 peak, while remaining modestly above late-2024 levels.
Past performance is not a reliable indicator of future results.
Him & Hers Health (HIMS): Capital.com analyst view
Hims & Hers Health has delivered a volatile journey over the past two years, ranging from the mid-$20s in late 2024 to a spike above $60 in early 2025, before easing back towards the high-$20s by early February 2026. This pattern reflects shifting market expectations around digital health and subscription-based care, with periods of optimism giving way to phases of profit-taking and reassessment as growth, profitability and valuation considerations interact.
From a fundamental perspective, the company’s direct-to-consumer telehealth model, including expansion into areas such as weight management and primary care, is often cited as a potential longer-term revenue opportunity. At the same time, the model exposes the business to competitive intensity and regulatory developments around online prescribing and marketing. Increased scrutiny of compounded medicines and decisions by high-profile partners may act as headwinds for sentiment, while a more supportive regulatory backdrop or successful adaptation of the business model could help stabilise perceptions over time.
Capital.com’s client sentiment for Him & Hers Health CFDs
As of 2 February 2026, Capital.com client positioning in Hims & Hers Health CFDs shows buyers at 97.8% versus sellers at 2.3%, indicating a heavily one-sided skew towards long positions and a net long bias of around 95.5 percentage points. This snapshot reflects open positions on the Capital.com platform and may change over time.
Summary – Him & Hers Health 2026
- Hims & Hers Health (HIMS) trades around $27.18 as of 3:30pm UTC on 2 February 2026, following a volatile two-year round trip from the mid-$20s to above $60 and back towards the high-$20s.
- The share price peaked near the low-$70s in February 2025 before trending lower through the second half of the year, ending 2025 at about $32.81 and continuing to drift lower into early 2026.
- Daily technical indicators show price trading below its 20-, 50-, 100- and 200-day moving averages, clustered broadly from the low-$30s to the mid-$40s. The 14-day RSI near 32 and ADX above 30 point to a weak price structure within an established trend context.
- Company commentary continues to highlight its direct-to-consumer telehealth model and expansion into areas such as weight management as potential growth factors, while regulatory scrutiny, competition and partner decisions remain key considerations for sentiment.
Past performance is not a reliable indicator of future results.
FAQ
Who owns most of Hims & Hers Health stock?
Hims & Hers Health has a mixed ownership structure that includes institutional investors, company insiders and retail shareholders. Larger stakes are typically held by asset managers, investment funds and early backers, alongside holdings by the company’s founders and senior executives. Ownership levels can change over time due to portfolio rebalancing, share issuance or insider transactions, meaning reported positions represent snapshots rather than fixed indicators of long-term control or influence.
What is the five-year Hims & Hers Health share price forecast?
There is no single consensus five-year HIMS stock forecast. Longer-term projections vary widely and depend on assumptions around revenue growth, profitability, competition and regulation within digital healthcare. Analyst targets typically focus on shorter horizons, such as 12 months, and even these can differ substantially. As a result, longer-term forecasts are often best viewed as illustrative scenarios rather than reliable expectations of future price performance.
Is Hims & Hers Health a good stock to buy?
Whether Hims & Hers Health is considered a 'good' stock depends on individual objectives, risk tolerance and market views. Supportive perspectives often point to the company’s direct-to-consumer telehealth model and subscriber growth, while more cautious views highlight valuation sensitivity, competitive pressure and regulatory uncertainty. Share prices can reflect changing expectations over time, and past performance does not indicate future outcomes. This content is provided for informational purposes only and is not a recommendation to buy or sell any instrument.
Could Hims & Hers Health stock go up or down?
Like all publicly traded shares, Hims & Hers Health stock can move both higher and lower. Price movements may be influenced by earnings results, guidance updates, regulatory developments, competitive dynamics and broader market conditions. Sentiment-related factors, such as shifts in growth expectations or risk appetite, can also play a role. These drivers can interact in complex ways, contributing to uncertainty and potential volatility over short- and medium-term horizons.
Should I invest in Hims & Hers Health stock?
Deciding whether to invest in Hims & Hers Health stock is a personal decision that depends on individual financial circumstances, investment goals and risk appetite. Investing in shares involves the risk of capital loss, and outcomes are uncertain. Before making any decision, individuals may wish to conduct their own research and consider seeking independent financial advice. This content is for general information only and does not constitute investment advice.
Can I trade Hims & Hers Health CFDs on Capital.com?
Yes, you can trade Him & Hers Health CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.